Sign in
Username
Password
Lost your password?
Login
Login with Facebook
Login with Google
Login with LinkedIn
(close)
Search for:
Sign in
Register
Country Reports
InFocus
Europe
Asia-Pacific
Americas
Middle East & Africa
Legal & Regulatory
Sign in / Register
Country Reports
Americas
Asia-Pacific
Europe
Middle East & Africa
Vaccines
Legal & Regulatory
Shop
Search for:
Library
Contributions
China
COVID-19
Cell & Gene Therapy
Vaccines
News Releases
Facts & Figures
Directory
Shop
Tagged with Alzheimer's
China: Green Valley Alzheimer’s Trial; Samsung Biologics…
A roundup of the latest from Chinese pharma, including Green Valley's upcoming US trial for an Alzheimer's drug inspired by algae; Samsung Biologics…
Save
Share
Aducanumab edges closer to Potential Approval: Next up, the…
In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…
Save
Share
Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…
Save
Share
Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…
Save
Share
Opinion: The Paradigm Shift Needed for Effective Alzheimer’s…
Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech…
Save
Share
Luis Calderon – General Manager, Biogen Mexico
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and…
Save
Share
Worried About Biogen’s Aducanumab? Don’t Be
Dr Neil Cashman examines the recent news around Biogen's Alzheimer's treatment aducanumab, assuages some investor fears, and underlines the…
Save
Share
Alzheimer’s Disease Treatment: Canadian-Led Innovation…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen's aducanumab on the search for Alzheimer's Disease (AD) treatments, and…
Save
Share
Gunilla Osswald – CEO, BioArctic, Sweden
BioArctic is a Swedish biopharma company with the vision to become a world-leader in the research and development of disease-modifying treatments for…
Save
Share
Sweden’s BioArctic: A Potential Paradigm Shift in Alzheimer’s…
Swedish biotech BioArctic, in collaboration with Japanese firm Eisai, has seen positive Phase IIb results for its BAN2401 antibody – potentially the…
Save
Share
Alzheimer’s Disease R&D Expenditure Snapshot 2019
Alzheimer's drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom, "Except for…
Save
Share
The Ongoing Battle to Crack the Alzheimer’s Treatment Dilemma
David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness…
Save
Share
Page: 1 |
1
2
interviews
{"post_type":["article","interviews","legal_article","facts","infocus","sponsored"],"post_status":"publish","posts_per_page":12,"max_num_pages":-1,"paged":1,"meta_query":[{"key":"related","value":" Alzheimer's","compare":"LIKE"}]}
We use cookies to ensure that we give you the best experience on our site. For more info
click here
ACCEPT